thus preventing damage to the corneal endothelium. The stiffening effect is concentrated in the anterior 200–300 µm of the cornea due to the high absorption of UV light in this area.

In this Healio Video Perspective from Hawaiian Eye 2025, Greg Kunst, CEO of Aurion Biotech, discusses positive phase 1/2 data for the company’s cell therapy for corneal endothelial disease.

Vyznova (neltependocel, formerly AURN001) is the world's first allogeneic cell therapy for corneal endothelial disease, according to the Seattle, Washington-based company. It already has ...

Important insights into the mechanisms behind Fuchs endothelial corneal dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers.

In 2022, doctors in Japan performed a transplant of iPS cell-derived corneal endothelial cells iPS cell derived-corneal endothelial cell transplants are injected and take about 20 minutes In Japan ...

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...